Literature DB >> 33443484

A Live Video Mind-Body Treatment to Prevent Persistent Symptoms Following Mild Traumatic Brain Injury: Protocol for a Mixed Methods Study.

Jonathan Greenberg1, Tanya Singh1, Grant L Iverson2,3,4, Noah D Silverberg5,6, Eric A Macklin7,8, Robert A Parker7,8, Joseph T Giacino9,10, Gloria Y Yeh7,11, Ana-Maria Vranceanu1.   

Abstract

BACKGROUND: Every year, approximately 42 million people sustain a mild traumatic brain injury (mTBI, also known as concussion), with particularly high rates among college-aged individuals. A substantial proportion of these people (44%-64%) develop persistent symptoms that are challenging to treat, costly, and associated with significant disability. Anxiety has emerged as a risk factor for progression from acute to persistent mTBI symptoms.
OBJECTIVE: This study aims to develop, adapt, and establish the feasibility of the Toolkit for Optimal Recovery after Concussions (TOR-C), an innovative mind-body program aimed at preventing persistent symptoms among young adults with mTBI and comorbid anxiety. Here, we describe the proposed study design, methodology, measurement, and treatment manuals.
METHODS: In phase 1, we will conduct individual, live video qualitative interviews (up to n=20) with college-aged individuals with mTBI and comorbid anxiety to inform adaptation of the intervention and study procedures. In phase 2, an open pilot of the live video TOR-C (n=5) with exit interviews will be conducted to explore the initial feasibility, acceptability, and credibility of the program and to refine the study procedures. Phase 3 will involve conducting a feasibility randomized controlled trial (N=50) of the TOR-C versus a health education control (Health Enhancement for Concussions; HE-C), both delivered via live video, to establish feasibility of recruitment procedures (screening, eligibility, and enrollment) and data collection; feasibility, credibility, and acceptability of the live video TOR-C and HE-C (adherence, retention, fidelity, and satisfaction) following prespecified benchmarks; and a signal of improvement in outcomes.
RESULTS: Phase 1 of the study has been approved by the Massachusetts General Hospital Institutional Review Board. Study completion is anticipated by early 2025.
CONCLUSIONS: We will develop and test the first mind-body intervention focused on prevention of persistent symptoms following mTBI in young adults with comorbid anxiety problems. This will allow us to establish feasibility markers in postconcussive symptoms, anxiety, disability, and fear avoidance to inform a future efficacy trial of the TOR-C versus HE-C. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/25746. ©Jonathan Greenberg, Tanya Singh, Grant L Iverson, Noah D Silverberg, Eric A Macklin, Robert A Parker, Joseph T Giacino, Gloria Y Yeh, Ana-Maria Vranceanu. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 14.01.2021.

Entities:  

Keywords:  anxiety; intervention development; mild traumatic brain injury; mixed methods

Year:  2021        PMID: 33443484      PMCID: PMC7843203          DOI: 10.2196/25746

Source DB:  PubMed          Journal:  JMIR Res Protoc        ISSN: 1929-0748


  59 in total

1.  Prolonged Activity Restriction After Concussion: Are We Worsening Outcomes?

Authors:  Marc DiFazio; Noah D Silverberg; Michael W Kirkwood; Raquel Bernier; Grant L Iverson
Journal:  Clin Pediatr (Phila)       Date:  2015-06-29       Impact factor: 1.168

2.  Consensus statement on concussion in sport-the 5th international conference on concussion in sport held in Berlin, October 2016.

Authors:  Paul McCrory; Willem Meeuwisse; Jiří Dvořák; Mark Aubry; Julian Bailes; Steven Broglio; Robert C Cantu; David Cassidy; Ruben J Echemendia; Rudy J Castellani; Gavin A Davis; Richard Ellenbogen; Carolyn Emery; Lars Engebretsen; Nina Feddermann-Demont; Christopher C Giza; Kevin M Guskiewicz; Stanley Herring; Grant L Iverson; Karen M Johnston; James Kissick; Jeffrey Kutcher; John J Leddy; David Maddocks; Michael Makdissi; Geoff T Manley; Michael McCrea; William P Meehan; Shinji Nagahiro; Jon Patricios; Margot Putukian; Kathryn J Schneider; Allen Sills; Charles H Tator; Michael Turner; Pieter E Vos
Journal:  Br J Sports Med       Date:  2017-04-26       Impact factor: 13.800

3.  Sample size policy for qualitative studies using in-depth interviews.

Authors:  Shari L Dworkin
Journal:  Arch Sex Behav       Date:  2012-12

4.  Virtual mind-body treatment for adolescents with neurofibromatosis: Study protocol for a single-blind randomized controlled trial.

Authors:  Mira Reichman; Eric Riklin; Eric Macklin; Ana-Maria Vranceanu
Journal:  Contemp Clin Trials       Date:  2020-07-04       Impact factor: 2.226

Review 5.  Exercise is Medicine for Concussion.

Authors:  John J Leddy; Mohammad N Haider; Michael Ellis; Barry S Willer
Journal:  Curr Sports Med Rep       Date:  2018-08       Impact factor: 1.733

6.  Feasibility and Potential Benefits of a Web-Based Intervention Delivered Acutely After Mild Traumatic Brain Injury in Adolescents: A Pilot Study.

Authors:  Brad G Kurowski; Shari L Wade; Judith W Dexheimer; Jenna Dyas; Nanhua Zhang; Lynn Babcock
Journal:  J Head Trauma Rehabil       Date:  2016 Nov/Dec       Impact factor: 2.710

7.  Rates of symptom reporting following traumatic brain injury.

Authors:  Sureyya Dikmen; Joan Machamer; Jesse R Fann; Nancy R Temkin
Journal:  J Int Neuropsychol Soc       Date:  2010-03-01       Impact factor: 2.892

8.  A brief measure for assessing generalized anxiety disorder: the GAD-7.

Authors:  Robert L Spitzer; Kurt Kroenke; Janet B W Williams; Bernd Löwe
Journal:  Arch Intern Med       Date:  2006-05-22

9.  The Behavioural Responses to Illness Questionnaire (BRIQ): a new predictive measure of medically unexplained symptoms following acute infection.

Authors:  Meagan Spence; Rona Moss-Morris; Trudie Chalder
Journal:  Psychol Med       Date:  2005-04       Impact factor: 7.723

10.  Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT.

Authors:  Ana-Maria Vranceanu; Eric Riklin; Vanessa L Merker; Eric A Macklin; Elyse R Park; Scott R Plotkin
Journal:  Neurology       Date:  2016-07-22       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.